Discontinued — last reported Q4 '25
Products & Services · Revenue
Sales-based milestone earned — Revenue
Over 3 years (FY 2021 to FY 2025), Sales-based milestone earned — Revenue shows a downward trend with a -100.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ3 2019
Last reportedQ4 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong commercial performance of licensed products, while a decrease suggests either a lack of new milestone triggers or a decline in the market performance of the underlying assets.
Detailed definition
This metric represents revenue recognized from contractual milestone payments triggered when a licensed product or colla...
Peer comparison
Common in biopharmaceutical companies with extensive R&D collaboration agreements, often categorized under 'collaboration revenue' or 'milestone payments' by peers.
Metric ID:
regn_segment_sales_based_milestones_earned_revenuesHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $50.00M | $0.00 | $50.00M | $0.00 | $0.00 | $50.00M | $0.00 | $0.00 | $50.00M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | -100.0% | — | -100.0% | — | — | -100.0% | — | — | -100.0% | — | — | — | — | — |
| YoY Change | — | — | — | — | — | -100.0% | — | -100.0% | — | — | -100.0% | -100.0% | — | — | — | — |
Range$0.00 – $50.00M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's sales-based milestone earned — revenue?
- Regeneron Pharmaceuticals (REGN) reported sales-based milestone earned — revenue of $0.00 in Q4 2025.
- What is the long-term trend for Regeneron Pharmaceuticals's sales-based milestone earned — revenue?
- Over 3 years (2021 to 2025), Regeneron Pharmaceuticals's sales-based milestone earned — revenue has grown at a -100.0% compound annual growth rate (CAGR), from $50.00M to $0.00.
- What does sales-based milestone earned — revenue mean?
- Revenue earned from partners when a drug reaches specific sales targets.